WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
The LatestI was the first person in the world to survive RABIES without a vaccinePaige Bueckers and UConn to host JuJu Watkins and USC in DecemberReds' TJ Friedl placed on injured list with fractured left thumbMeghan Markle wore nearly £120,000 of new clothing and jewellery in 72 hours on her 'quasiHong Kong calls for respect of its overseasKentucky governor to speak out against strict abortion ban in neighboring TennesseeVan driver dies in rearRooney posts an 18Hedge fund operators go on trial after multibillion
2.472s , 5871.4453125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wonders news portal